Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: The APERT study

Thuan Le, James D. Cherry, Swei Ju Chang, Maria Deloria Knoll, Martin L. Lee, Steve Barenkamp, David Bernstein, Robert Edelman, Kathryn M. Edwards, David Greenberg, Wendy Keitel, John Treanor, Joel I. Ward

Research output: Contribution to journalArticle

Abstract

As part of a prospective acellular pertussis (ACP) vaccine efficacy trial, 5 serum samples were obtained, over an 18-month period, from 101 ACP-vaccine recipients and 99 control subjects, to assess ACP antibody response and decay. Immunoglobulin (Ig) G and IgA antibodies to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae 2/3 (FIM) were measured by enzyme-linked immunosorbant assay, and titers of agglutinin were determined. Of the subjects, 16%-19% had preimmunization values of antibodies to PT that were above the assay's limit of quantitation (LOQ); in contrast, 36%-63% of the subjects had preimmunization values of antibodies to FHA, PRN, or FIM that were above the LOQ. Substantial increases in titers of IgG and IgA antibodies to the 3 ACP antigens (PT, FHA, and PRN) were observed. Over the 18-months, the percent decay in IgG and IgA antibodies ranged from 56% to 73% and from 57% to 70%, respectively; the IgG antibody response and decay suggests that geometric mean titers likely remain above the LOQ for 2-9 years and above the threshold of detection for 4-13 years. These findings support the use of ACP booster immunizations for adolescents and adults, to provide sustained levels of antibody.

Original languageEnglish (US)
Pages (from-to)535-544
Number of pages10
JournalJournal of Infectious Diseases
Volume190
Issue number3
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Fingerprint

Acellular Vaccines
Pertussis Vaccine
Antibody Formation
Immunization
Antibodies
Whooping Cough
Pertussis Toxin
Hemagglutinins
Immunoglobulin G
Immunoglobulin A
Secondary Immunization
Agglutinins
Antigens
Enzymes
Serum
pertactin

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine : The APERT study. / Le, Thuan; Cherry, James D.; Chang, Swei Ju; Knoll, Maria Deloria; Lee, Martin L.; Barenkamp, Steve; Bernstein, David; Edelman, Robert; Edwards, Kathryn M.; Greenberg, David; Keitel, Wendy; Treanor, John; Ward, Joel I.

In: Journal of Infectious Diseases, Vol. 190, No. 3, 01.08.2004, p. 535-544.

Research output: Contribution to journalArticle

Le, T, Cherry, JD, Chang, SJ, Knoll, MD, Lee, ML, Barenkamp, S, Bernstein, D, Edelman, R, Edwards, KM, Greenberg, D, Keitel, W, Treanor, J & Ward, JI 2004, 'Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: The APERT study', Journal of Infectious Diseases, vol. 190, no. 3, pp. 535-544. https://doi.org/10.1086/422035
Le, Thuan ; Cherry, James D. ; Chang, Swei Ju ; Knoll, Maria Deloria ; Lee, Martin L. ; Barenkamp, Steve ; Bernstein, David ; Edelman, Robert ; Edwards, Kathryn M. ; Greenberg, David ; Keitel, Wendy ; Treanor, John ; Ward, Joel I. / Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine : The APERT study. In: Journal of Infectious Diseases. 2004 ; Vol. 190, No. 3. pp. 535-544.
@article{f75eda2c94da469489451df50cd6350b,
title = "Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: The APERT study",
abstract = "As part of a prospective acellular pertussis (ACP) vaccine efficacy trial, 5 serum samples were obtained, over an 18-month period, from 101 ACP-vaccine recipients and 99 control subjects, to assess ACP antibody response and decay. Immunoglobulin (Ig) G and IgA antibodies to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae 2/3 (FIM) were measured by enzyme-linked immunosorbant assay, and titers of agglutinin were determined. Of the subjects, 16{\%}-19{\%} had preimmunization values of antibodies to PT that were above the assay's limit of quantitation (LOQ); in contrast, 36{\%}-63{\%} of the subjects had preimmunization values of antibodies to FHA, PRN, or FIM that were above the LOQ. Substantial increases in titers of IgG and IgA antibodies to the 3 ACP antigens (PT, FHA, and PRN) were observed. Over the 18-months, the percent decay in IgG and IgA antibodies ranged from 56{\%} to 73{\%} and from 57{\%} to 70{\%}, respectively; the IgG antibody response and decay suggests that geometric mean titers likely remain above the LOQ for 2-9 years and above the threshold of detection for 4-13 years. These findings support the use of ACP booster immunizations for adolescents and adults, to provide sustained levels of antibody.",
author = "Thuan Le and Cherry, {James D.} and Chang, {Swei Ju} and Knoll, {Maria Deloria} and Lee, {Martin L.} and Steve Barenkamp and David Bernstein and Robert Edelman and Edwards, {Kathryn M.} and David Greenberg and Wendy Keitel and John Treanor and Ward, {Joel I.}",
year = "2004",
month = "8",
day = "1",
doi = "10.1086/422035",
language = "English (US)",
volume = "190",
pages = "535--544",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine

T2 - The APERT study

AU - Le, Thuan

AU - Cherry, James D.

AU - Chang, Swei Ju

AU - Knoll, Maria Deloria

AU - Lee, Martin L.

AU - Barenkamp, Steve

AU - Bernstein, David

AU - Edelman, Robert

AU - Edwards, Kathryn M.

AU - Greenberg, David

AU - Keitel, Wendy

AU - Treanor, John

AU - Ward, Joel I.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - As part of a prospective acellular pertussis (ACP) vaccine efficacy trial, 5 serum samples were obtained, over an 18-month period, from 101 ACP-vaccine recipients and 99 control subjects, to assess ACP antibody response and decay. Immunoglobulin (Ig) G and IgA antibodies to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae 2/3 (FIM) were measured by enzyme-linked immunosorbant assay, and titers of agglutinin were determined. Of the subjects, 16%-19% had preimmunization values of antibodies to PT that were above the assay's limit of quantitation (LOQ); in contrast, 36%-63% of the subjects had preimmunization values of antibodies to FHA, PRN, or FIM that were above the LOQ. Substantial increases in titers of IgG and IgA antibodies to the 3 ACP antigens (PT, FHA, and PRN) were observed. Over the 18-months, the percent decay in IgG and IgA antibodies ranged from 56% to 73% and from 57% to 70%, respectively; the IgG antibody response and decay suggests that geometric mean titers likely remain above the LOQ for 2-9 years and above the threshold of detection for 4-13 years. These findings support the use of ACP booster immunizations for adolescents and adults, to provide sustained levels of antibody.

AB - As part of a prospective acellular pertussis (ACP) vaccine efficacy trial, 5 serum samples were obtained, over an 18-month period, from 101 ACP-vaccine recipients and 99 control subjects, to assess ACP antibody response and decay. Immunoglobulin (Ig) G and IgA antibodies to pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae 2/3 (FIM) were measured by enzyme-linked immunosorbant assay, and titers of agglutinin were determined. Of the subjects, 16%-19% had preimmunization values of antibodies to PT that were above the assay's limit of quantitation (LOQ); in contrast, 36%-63% of the subjects had preimmunization values of antibodies to FHA, PRN, or FIM that were above the LOQ. Substantial increases in titers of IgG and IgA antibodies to the 3 ACP antigens (PT, FHA, and PRN) were observed. Over the 18-months, the percent decay in IgG and IgA antibodies ranged from 56% to 73% and from 57% to 70%, respectively; the IgG antibody response and decay suggests that geometric mean titers likely remain above the LOQ for 2-9 years and above the threshold of detection for 4-13 years. These findings support the use of ACP booster immunizations for adolescents and adults, to provide sustained levels of antibody.

UR - http://www.scopus.com/inward/record.url?scp=3242801314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242801314&partnerID=8YFLogxK

U2 - 10.1086/422035

DO - 10.1086/422035

M3 - Article

C2 - 15243929

AN - SCOPUS:3242801314

VL - 190

SP - 535

EP - 544

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -